PharmaCyte Biotech, Inc. is a biotechnology company, which is focused on developing cellular therapies for cancer based upon a proprietary cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including locally advanced, inoperable pancreatic cancer (LAPC) will be developed. The Cell-in-a-Box encapsulation technology potentially enables genetically engineered live human cells to be used as a means to produce various biologically active molecules. The technology is intended to result in the formation of pinhead-sized cellulose-based porous capsules in which genetically modified live human cells can be encapsulated and maintained. In a laboratory setting, this proprietary live cell encapsulation technology has been shown to create a micro-environment in which encapsulated cells survive and flourish.
äŒæ¥ã³ãŒãPMCB
äŒç€ŸåPharmaCyte Biotech Inc
äžå Žæ¥Sep 11, 2003
æé«çµå¶è²¬ä»»è
ãCEOãSilverman (Joshua N)
åŸæ¥å¡æ°2
蚌åžçš®é¡Ordinary Share
æ±ºç®ææ«Sep 11
æ¬ç€Ÿæåšå°3960 Howard Hughes Parkway, Suite 500
éœåžLAS VEGAS
蚌åžååŒæNASDAQ OMX - NASDAQ BASIC
åœUnited States of America
éµäŸ¿çªå·89169
é»è©±çªå·19175952850
ãŠã§ããµã€ãhttps://pharmacyte.com/
äŒæ¥ã³ãŒãPMCB
äžå Žæ¥Sep 11, 2003
æé«çµå¶è²¬ä»»è
ãCEOãSilverman (Joshua N)
éå»5幎éã®é
åœéç·æ¯æé¡ã¯
0.00
ç±³ãã«ã§ããã

ããŒã¿ãªã